Acting On Glycosyl Compound (3.2) (e.g., Glycosidases Lysozyme, Nucleosidases, Cellulase, Etc.) Patents (Class 424/94.61)
  • Patent number: 11969436
    Abstract: To provide a method for evaluating or selecting an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens, and an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens. A method for evaluating or selecting an agent for reducing sensory irritation caused by parabens, comprising the following steps (1) to (3): (1) a step of contacting cells capable of expressing CES1 with a test substance; (2) a step of measuring expression of CES1 in the cells; (3) a step of evaluating a test substance which promotes expression of CES1 as an agent for reducing sensory irritation caused by parabens based on the results measured in (2).
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 30, 2024
    Assignee: Kao Corporation
    Inventors: Rie Ninomiya, Takafumi Nishijima, Noriko Sato
  • Patent number: 11684603
    Abstract: Disclosed are methods for ameliorating glycocalyx damage by administering a neuraminidase inhibitor. Also disclosed are methods for treating endothelial dysfunction and for improving flow mediated dilation.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: June 27, 2023
    Assignee: CURATORS OF THE UNIVERSITY OF MISSOURI UNIVERSITY
    Inventors: Luis A. Martinez-Lemus, Christopher A. Foote, Jaume Padilla
  • Patent number: 11596710
    Abstract: Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: March 7, 2023
    Inventors: Syed H. Askari, Yeon S. Choi
  • Patent number: 11584921
    Abstract: Provided herein is a stabilized DNase I polypeptide containing a non-standard amino acid that maintains enzymatic activity even under harsh conditions, such as reducing environments. The stabilized DNase I polypeptide has enzymatic activity in reducing environments that is higher than a corresponding DNase I polypeptide without the non-standard amino acids under the same conditions. Also provided herein are polynucleotides encoding the stabilized DNase I polypeptide, cells for expressing and/or producing the stabilized DNase I polypeptide, and methods of use of the stabilized DNase I polypeptide.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: February 21, 2023
    Assignee: GRO Biosciences Inc.
    Inventors: Daniel J. Mandell, Christopher J. Gregg, Peter B. Stranges
  • Patent number: 11413306
    Abstract: The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject in need thereof. Also provided is an alginate oligomer for use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject and a product containing an alginate oligomer and further pharmaceutical for the treatment of intestinal microbial overgrowth and/or a CFTR modulator as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 16, 2022
    Assignee: ALGIPHARMA AS
    Inventors: Arne Dessen, Philip Rye
  • Patent number: 11345904
    Abstract: The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lysosomal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 31, 2022
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Saeed Moshashaee, Jason K. Pinkstaff, Adam Shaywitz, Natalie Ciaccio
  • Patent number: 11324766
    Abstract: The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection-induced host inflammation and/or to promote recovery from a respiratory pathogen infection-induced host inflammation in a subject.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: May 10, 2022
    Assignee: Glycosyn LLC
    Inventors: Ardythe L. Morrow, David S. Newburg, John M. McCoy
  • Patent number: 11311029
    Abstract: A composition comprising branched fructan molecules derived from a fructan extract of perennial high sugar grass (HSG) selected from the group consisting of AberMagic cultivar, AberDart cultivar, and S48 (Lolium spp), and obtained by enzymic endo-hydrolase hydrolysis, wherein said branched fructan molecules have a molecular weight of between 0.3 to 3 kDa, and wherein at least 50% of the branched fructan molecules present in the composition have a molecular weight of between 0.48 and 1.9 kDa is provided. Also provided are feed or food supplement comprising such a composition, a method of producing a composition comprising branched fructan molecules, and a method of making a feed or foodstuff.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: April 26, 2022
    Assignee: Aberystwyth University
    Inventors: Andrew John Lee, Joseph Gallagher, Steven Anthony Fish, Stephen Michael Morris
  • Patent number: 11291209
    Abstract: Compositions and uses involving L. monocytogenes PssZ, as well as homologs, variants, and fragments thereof, are described.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: April 5, 2022
    Assignee: University of Wyoming
    Inventors: Mark Gomelsky, Kurt Miller, Volkan Köseo{hacek over (g)}lu
  • Patent number: 11291236
    Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 5, 2022
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Brown, Albert Archie Stone
  • Patent number: 11260112
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: March 1, 2022
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Richard Fahrner, Jing Pan, Teresa Leah Wright, Pericles Calias
  • Patent number: 11242516
    Abstract: A method for ex vivo treating blood or plasma is provided. The method includes (a) ex vivo contacting a blood or plasma with an enzyme composition to react the enzyme composition with the blood or plasma, wherein the enzyme composition is capable of eliminating electronegative low-density lipoprotein from the blood or plasma by the activity of the enzyme composition, and the enzyme composition is selected from a group consisting of: a first enzyme for eliminating a glycan residue of an electronegative low-density lipoprotein (LDL); a second enzyme for eliminating ceramide carried by a electronegative low-density lipoprotein (LDL); and a combination thereof; and (b) terminating contact between the blood or plasma and the enzyme composition to terminate the reaction of the enzyme composition with the blood or plasma.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 8, 2022
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Pei-Yi Tsai, Chih-Hung Chen, Yi-Hung Lin, Chih-Chieh Huang, Hsin-Hsin Shen, Liang-Yin Ke, Chu-Huang Chen
  • Patent number: 11241486
    Abstract: Methods and compositions for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infection using polypeptides having sialidase activity are provided herein.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: February 8, 2022
    Assignee: Ansun Biopharma, Inc.
    Inventor: Ronald D. Moss
  • Patent number: 11225648
    Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: January 18, 2022
    Assignee: Protalix Ltd.
    Inventors: Lilach Chen Zeltsburg, Ilya Ruderfer, Avidor Shulman, Liat Fux, Yulia Ugortsev, Hagit Neta, Sivan Gelley, Elad Lavee Laviad, Yoseph Shaaltiel
  • Patent number: 11155829
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 26, 2021
    Inventors: Jennifer Barry, Catherine Clark, Ryan Gerber, Amy Lum, John Mathis, Azalea Ong, Brooke Peterson-Burch, Thomas C. Wolfe, Weiping Xie, Nasser Yalpani, Xiaohong Zhong
  • Patent number: 11141546
    Abstract: A system and methods for the delivery of oxygen through a body cavity of a subject using oxygen microbubbles. Through circulation of oxygen microbubbles through the body cavity, oxygen and carbon dioxide exchange may occur. Overall improvement in extending survival rate time during emergency situations caused by pulmonary or similar oxygen-intake restricting injury and/or failure may be achieved through use of the invented system and methods.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: October 12, 2021
    Assignees: The Regents of the University of Colorado, a Body Corporate, Board of Regents of the University of Nebraska
    Inventors: Mark A. Borden, Benjamin S. Terry
  • Patent number: 11124460
    Abstract: Methods for stimulating plant growth and/or promoting plant health using free enzymes or recombinant microorganisms that overexpress enzymes are provided. Plant seeds coated with free enzymes or recombinant microorganisms that overexpress enzymes are also provided. Compositions comprising a fertilizer and an enzyme or a recombinant microorganism that overexpresses an enzyme are provided. Modified enzymes having ACC deaminase activity, recombinant microorganisms expressing the modified enzymes, plant seeds treated with the modified enzymes or recombinant microorganisms, and methods for stimulating plant growth and/or promoting plant health using the modified enzymes or recombinant microorganisms are also provided.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 21, 2021
    Assignee: Spogen Biotech Inc.
    Inventors: Brian M. Thompson, Jorg Augustin
  • Patent number: 11116850
    Abstract: This invention relates to viral vectors for delivery of alpha-L-iduronidase to the cornea of a subject and methods of using the same for treatment and prevention of corneal clouding and blindness in a subject due to mucopolysaccharidosis I.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: September 14, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Matthew Louis Hirsch, Richard Jude Samulski
  • Patent number: 11058675
    Abstract: Provided herein are small molecule-inhibitors of site-specific O-glycosylation and the identification of such using cell-based fluorescent biosensors. Also provided herein are methods of treating kidney disease and cancer, such as breast cancer.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 13, 2021
    Assignee: Carnegie Mellon University
    Inventors: Adam D. Linstedt, Lina Song, Collin Bachert
  • Patent number: 11034943
    Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: June 15, 2021
    Assignee: biOasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Patent number: 10898534
    Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: January 26, 2021
    Assignee: NATUREX Inc.
    Inventors: Emilie Annie Claudie Fromentin, Douglas Andrew Klaiber, Daniel David Souza
  • Patent number: 10881590
    Abstract: A wet wiper for cleaning an oral cavity or an oral appliance. The wet wiper comprises a water insoluble substrate and a physiologically acceptable cleansing composition. Methods for cleansing oral cavities and oral appliances are also provided, such methods comprising the step of contacting the surface of an oral cavity or an oral appliance with a wet wiper of the present invention for a sufficient time to permit cleaning.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: January 5, 2021
    Assignee: Oral Health Technologies, LLC
    Inventors: Robert Eugene Tricca, Malia Mueller Smith
  • Patent number: 10857075
    Abstract: A wet wiper for cleaning accumulated oral debris from removable dental appliances. The wet wiper comprises (a) a water insoluble substrate; and (b) a physiologically acceptable cleansing composition, said cleansing composition comprising: a solution of water and a flavorant, wherein said water is up to about 97% by weight of said cleansing composition; and said flavorant is about 0.001% to about 5% by weight of said cleansing composition. Methods for cleaning removable dental appliances are also provided, such methods comprising the step of contacting, for a time sufficient to reduce oral debris, the removable dental appliances, with a wet wiper of the present invention.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: December 8, 2020
    Assignee: Oral Health Technologies, LLC
    Inventors: Robert Eugene Tricca, Malia Mueller Smith
  • Patent number: 10813983
    Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: October 27, 2020
    Assignee: CONTRAFECT CORPORATION
    Inventors: Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Han Lee, Brent Schneider
  • Patent number: 10792343
    Abstract: A vector have an expression cassette containing have a hIDUA gene has a sequence of SEQ ID NO: 1 (FIG. 1) or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be a production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: October 6, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Brittney L. Gurda
  • Patent number: 10751363
    Abstract: A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: August 25, 2020
    Assignee: AlgiPharma AS
    Inventors: Arne Dessen, Astrid Hilde Myrset, Philip Rye
  • Patent number: 10675336
    Abstract: In various aspects, the invention relates to immune tolerant glycosidase therapy. The invention provides methods for treating or preventing infectious disease, including chronic viral infections, and highly contagious infectious agents that present an ongoing challenge for the immune system. The compositions and treatment regimens find use with other antiviral or antimicrobial therapies, as well as in conjunction with vaccination to boost effectiveness and/or extend the duration of protective effect. In certain embodiments, the regimen described herein reduces or eliminates the need for administration of other traditional antiviral or antimicrobial therapies. In various embodiments, the invention finds use in immunocompromised patients to boost immune function.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 9, 2020
    Inventor: Ellis Kline
  • Patent number: 10653613
    Abstract: Trp-containing peptides, preferably from hen's egg hydrolysate can increase the Cys levels in blood serum. This results in increased keratin production, and enhances growth, appearance, and/or volume in keratin-containing tissue including skin, hair, and/or nails.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: May 19, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Regina Goralczyk, Hasan Mohajeri, Jonas Wittwer Schegg
  • Patent number: 10646554
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: May 12, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
  • Patent number: 10639289
    Abstract: The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: May 5, 2020
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Lianwen Qi, Lei Zhang, Tingting Wei, Yong Fan
  • Patent number: 10603364
    Abstract: The invention provides compositions and methods for effective lysosomal targeting mediated by SORT1. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Sanfilippo syndrome type B.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: March 31, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Michael F. Concino, Bettina Strack-Logue, Muthuraman Meiyappan, Angela W. Norton, Bohong Zhang, Andrea Iskenderian, Jianwen Feng, Kevin Holmes, Jing Pan
  • Patent number: 10533208
    Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: January 14, 2020
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Ida Annunziata, Alessandra D'Azzo
  • Patent number: 10501730
    Abstract: Variants of mannanase, compositions including the variants, to methods for their production and to methods of using the variants to degrade and modify mannan containing material.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 10, 2019
    Assignee: AB ENZYMES OY
    Inventors: Taija Leinonen, Leena Valtakari, Michael Seefried, Kari Juntunen, Terhi Puranen
  • Patent number: 10358636
    Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: July 23, 2019
    Assignees: STEALTH BIOLOGICS, LLC, TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Karl E. Griswold, Chris Bailey-Kellogg, Yoonjoo Choi, Kristina Blazanovic, Hongliang Zhao, Deeptak Verma
  • Patent number: 10357542
    Abstract: The present invention provides composition and methods for diagnosis and treatment of lysosomal storage diseases and their diagnosis and treatment, including Gaucher's Disease and Tay-Sachs disease, and particularly which utilize progranulin (PGRN), or active PGRN peptides, including atsttrin. The invention also provides animal models of lysosomal storage diseases, including Gaucher's Disease and Tay-Sachs disease, based on or including PGRN mutations including PGRN null mutants and PGRN gene knock outs.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 23, 2019
    Assignee: New York University
    Inventors: Chuanju Liu, Jinlong Jian
  • Patent number: 10328128
    Abstract: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: June 25, 2019
    Assignee: Ansun Biopharma, Inc.
    Inventor: Ronald B. Moss
  • Patent number: 10301629
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: May 28, 2019
    Assignee: PORTAGE PHARMACEUTICALS LTD.
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Patent number: 10301374
    Abstract: A method of producing collagen from hydrolyzed egg membrane includes combining 95% ethanol, cold water, a bacterial pH neutral protease and/or an alkaline bacterial protease, a pH neutral bacterial metalloendopeptidase, sodium bisulfite, and egg membrane. Once combined, the solution is mixed slowly and then heated to a desired pH range and temperature. Once a desired temperature is reached, the heated solution is set aside to digest for a prolonged period of time. Next, the digested solution is centrifuged and collected to form a filtered solution. Finally, the filtered solution is spray dried and packaged.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: May 28, 2019
    Inventor: Robert den Hoed
  • Patent number: 10251873
    Abstract: Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing ?-galactosidase A activity in the patient.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: April 9, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10239798
    Abstract: Disclosed are methods of enhancing plant growth, comprising treating seed at least one month prior to planting with an effective amount of a plant signal molecule, wherein upon harvesting the plant exhibits at least one of increased plant yield measured in terms of bushels/acre, increased root number, increased root length, increased root mass, increased root volume and increased leaf area, compared to plants harvested from untreated seed, or compared to plants harvested from seed treated with the signal molecule just prior to or within a week or less of planting.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 26, 2019
    Assignee: NOVOZYMES BIOAG A/S
    Inventors: R. Stewart Smith, Ahsan Habib, John Kosanke
  • Patent number: 10208299
    Abstract: Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 19, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Russell Gotschall, Hung V. Do
  • Patent number: 10206396
    Abstract: Disclosed are methods of enhancing plant growth, comprising treating plant seed or the plant that germinates from the seed with an effective amount of at least one chitooligosaccharide, wherein upon harvesting the plant exhibits at least one of increased plant yield measured in terms of bushels/acre, increased root number, increased root length, increased root mass, increased root volume and increased leaf area, compared to untreated plants or plants harvested from untreated seed.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: February 19, 2019
    Assignee: NOVOZYMES BIOAG A/S
    Inventors: R. Stewart Smith, Ahsan Habib
  • Patent number: 10167462
    Abstract: The present invention relates to polypeptides comprising an amino acid sequence exhibiting at least about 90% sequence identity with the sequence of SEQ ID NO: 1. Said polypeptides preferably degrade the peptidoglycan of Gram-negative bacteria, in particular of Pseudomonas and/or Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 1, 2019
    Assignee: LYSANDO AG
    Inventor: Irina Anosova
  • Patent number: 10160976
    Abstract: Disclosed herein is the nucleotide sequence of the Chromobacterium subtsugae genome. Also provided are the nucleotide sequences of open reading frames in the C. subtsugae genome (i.e., C. subtsugae genes). In addition, the amino acid sequences of proteins encoded by the C. subtsugae genome are provided. Nucleic acids, vectors and polypeptides comprising the aforementioned sequences are also provided. Homologues, functional fragments and conservative variants of the aforementioned sequences are also provided. Compositions having pesticidal, bioremedial and plant growth-promoting activities comprising C. subtsugae genes and proteins, and methods for the use of these compositions, are also provided.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: December 25, 2018
    Assignee: Marrone Bio Innovations, Inc.
    Inventors: Ana Lucia Cordova-Kreylos, Debora Wilk, Pamela Marrone
  • Patent number: 10137176
    Abstract: A vector having an expression cassette having a hIDUA gene having a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurle-Scheie and Scheie syndromes.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: The Trustee of the University of Pennsylvania
    Inventors: James M. Wilson, Brittney L. Gurda
  • Patent number: 10125228
    Abstract: Provided herein is a thermoplastic elastomer hydrogel and methods of making such. The hydrogel comprises a glass formed from poly(styrene)-b-poly(ethylene oxide) in which the coronal chain end has been functionalized with photodimerizable groups (AB-photo) and a liquid medium at a concentration between about 32:1 and about 2:1 liquid medium/AB-photo by weight. The hydrogel has a fatigue resistance to at least 500,000 compression cycles.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 13, 2018
    Assignee: Colorado State University Research Foundation
    Inventors: Travis S. Bailey, Nabila Asem Huq, Vincent F. Scalfani, John R. Ekblad, Alexander T. Leonard
  • Patent number: 10124126
    Abstract: A system and methods for the delivery of oxygen through a body cavity of a subject using oxygen microbubbles. Through circulation of oxygen microbubbles through the body cavity, oxygen and carbon dioxide exchange may occur. Overall improvement in extending survival rate time during emergency situations caused by pulmonary or similar oxygen-intake restricting injury and/or failure may be achieved through use of the invented system and methods.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: November 13, 2018
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Mark A. Borden, Benjamin S. Terry
  • Patent number: 10117830
    Abstract: A stable pharmaceutical composition that includes an active agent selected from 1-deoxynojirimycin, a pharmaceutically acceptable salt thereof, or a derivative thereof, and a buffer, wherein the stable pharmaceutical composition is capable of being parenterally administered to a human without deleterious health effects. Pompe disease is an example of a lysosomal storage disorder. Pompe disease is caused by a deficiency in the enzyme acid alpha-glucosidase (GAA). GAA metabolizes glycogen, a storage form of sugar used for energy, into glucose.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 6, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hing Char, Sergey Tesler, Jiping Yang, Enrique Dilone
  • Patent number: 10106837
    Abstract: This invention provides a single process that collects any and all target nucleic acids from a sample that can contain any of a number of biological species, including bacteria, viruses, or fungi, where the first step renders the sample nonhazardous and releases nucleic acids from cell structures, compartments, and molecular complexes that may hold them, the second step concentrates the target nucleic acids from even very highly dilute states, in the third step releases these in a form that, following dilution, makes them compatible with processes that amplify nucleic acids, both standard PCR as well as isothermal amplification protocols. The pre-amplification process involves ammonia solutions no more toxic than those found in the commercial product Windex, requires no electrical power, requires materials no more complex than water desalinization resin and salt, and can be used by inexperienced individuals.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: October 23, 2018
    Inventor: Steven A Benner
  • Patent number: RE48267
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 20, 2020
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe